<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383796</url>
  </required_header>
  <id_info>
    <org_study_id>TJDBPS02</org_study_id>
    <nct_id>NCT03383796</nct_id>
  </id_info>
  <brief_title>Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma</brief_title>
  <official_title>Randomized Clinical Trial Comparing Three Dimension Laparoscopic and Open Surgery for Perihiliar Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cholangiocarcinoma (CCA) is the most common biliary tract malignancy and the second most&#xD;
      common primary hepatic malignancy. The prognosis of CCA is dismal. Surgery is the only&#xD;
      potentially curative treatment, but the majority of patients present with advanced stage&#xD;
      disease, and recurrence after resection is common. It is classified into intrahepatic (iCCA),&#xD;
      perihilar (pCCA), and distal (dCCA) subtypes. Among all, pCCA is the most common subtype.&#xD;
&#xD;
      This is a prospective, randomized, controlled multicenter trial with two treatment arms,&#xD;
      three dimension laparoscopic approach versus open approach. The trial hypothesis is that&#xD;
      three dimension laparoscopic surgery has advantages in postoperative recoveries and be&#xD;
      equivalent in operation time, oncological results and long-term follow-up compared with open&#xD;
      counterpart. The duration of the entire trial is two years including prearrangement,&#xD;
      follow-up and analyses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Mortality was defined as any death that occurred in the 30 days after surgery or during the hospital stay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>24 months</time_frame>
    <description>Length of stay was defined as the postoperative time interval in days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>R0 Resection Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Negative margin rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bile leakage</measure>
    <time_frame>24 months</time_frame>
    <description>The drain bilirubin was monitored after surgery, any elevation for the bilirubin level or the diagnostic puncture proved bile fluid in abdominal cavity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNM Staging</measure>
    <time_frame>24 months</time_frame>
    <description>According to AJCC guideline, each patients TNM staging were recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate</measure>
    <time_frame>24 months</time_frame>
    <description>Complication Rate Measure Description Any complication mentioned in the protocol should be carefully record and analyzed, including postoperative hemorrhage, postoperative pancreatic fistula, etc.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cholangiocarcinoma, Perihilar</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>3D approach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three dimensional laparoscopic resection for pCCA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>open approach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open resection for pCCA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Three dimensional laparoscopic resection for pCCA</intervention_name>
    <description>Three dimensional laparoscopic resection for pCCA</description>
    <arm_group_label>3D approach</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open resection for pCCA</intervention_name>
    <description>Open resection for pCCA</description>
    <arm_group_label>open approach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven pCCA.&#xD;
&#xD;
          2. Highly presumed perihlar bile duct malignancy with difficulties to obtain histological&#xD;
             evidence.&#xD;
&#xD;
          3. Preoperative staging work up performed by upper abdomen enhanced CT scan.&#xD;
&#xD;
          4. The subject understands the nature of this trial and willing to comply.&#xD;
&#xD;
          5. Ability to provide written informed consent.&#xD;
&#xD;
          6. Patients treated with curative intent in accordance to international guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Distant metastases: peritoneal carcinomatosis, liver metastases, distant lymph node&#xD;
             metastases, involvement of other organs.&#xD;
&#xD;
          2. Subjects undergoing any part for hepatectomy.&#xD;
&#xD;
          3. Patients with high operative risk as defined by the American Society of&#xD;
             Anesthesiologists (ASA) score &gt;4.&#xD;
&#xD;
          4. Synchronous malignancy in other organs.&#xD;
&#xD;
          5. Palliative surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hang Zhang, M.D.</last_name>
      <phone>+8613407148260</phone>
      <email>okashiiyo@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Wang, Dr.</last_name>
      <phone>+8602783665314</phone>
      <email>wangmin0013128@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Renyi Qin</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Cholangiocarcinoma perihilar</keyword>
  <keyword>three dimension laparoscopic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

